title: Antiviral therapy for chronic hepatitis B in China.
abstract: The vaccination program against hepatitis B virus (HBV) has greatly reduced the incidence of HBV infection. However, almost one-fourth of the HBV infected patients worldwide are still located in China. The healthcare burden from chronic HBV infection is a big challenge for the Chinese government and clinicians. Antiviral therapy plays a central role in controlling chronic HBV infection and preventing the disease progression. However, due to the specific economic and medical system issues, the first-line antiviral agents recommended by the AASLD and EASL have not been widely used for Chinese patients. In this review, we will discuss some key issues in the area of antiviral treatment for chronic hepatitis B in China.
authors.affiliation: Department of Infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Zheng
authors.forename: Junzhong
authors.initials: J
authors.lastname: Wang
authors.forename: Dongliang
authors.initials: D
authors.lastname: Yang
mesh_terms: D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D002681:China; D004358:Drug Therapy / Q000379:methods; D004363:Drug Utilization; D006297:Health Services Accessibility; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans
chemical_list: D000998:Antiviral Agents